Table 7.
Representative products of GCs-based prodrugs in clinical trials.
| Registered number | Drug name | Adaptation disease | Stage | Country |
|---|---|---|---|---|
| EUCTR2017–003,590–33-DK | Prednisolone sodium phosphate | Asthma | Phase Ⅳ | Denmark |
| EUCTR2012–005,123–32-GB | Prednisolone sodium phosphate | Otitis media with effusion | Phase Ⅲ | United Kingdom |
| EUCTR2010–020,448–37-BE | Prednisolone sodium phosphate | Colitis | Phase Ⅱ | Belgium; Netherlands |
| CTR20131261 | Dex palmitate | Rheumatoid arthritis | PhaseⅡ | China |
| NCT05571046 | Betamethasone sodium phosphate | Radiculopathy lumbar | Phase Ⅳ | Turkey |
| NCT04734210 | Betamethasone sodium phosphate | Dry eye disease | Phase Ⅱ | United States |
| NCT04544683 | Dex sodium phosphate | Cervical radiculopathy; Cervical spondylosis; Disk, Herniated | Phase Ⅳ | United States |
| NCT04432012 | Dex sodium phosphate | Total knee replacement | Phase Ⅳ | Switzerland |
| CTRI/2020/04/024,470 | Dex sodium phosphate | Oral submucous fibrosis | PhaseⅡ /Phase Ⅲ |
India |
| NCT03823391 | ABBV-3373 (ADCs) | Rheumatoid arthritis | Phase Ⅱ | United States |
| NCT05512390 | ABBV-319 (ADCs) | B cell malignant tumor | Phase Ⅰ | United States |